Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Pancreatic Cancer Clinical Trials

113 recruiting trials for Pancreatic Cancer. Eligibility criteria explained in plain English.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
113
Total Trials
113
Recruiting Now
3
Phase 3 Trials
10
Sponsors

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGPhase 1NCT06238479

A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors

The purpose of this study is to find out whether the study drug, LY4101174, is safe, tolerable and effective in participants with select advanced or metastatic solid tumors. The...

Sponsor: Eli Lilly and CompanyEnrolling: 49020 locations
RECRUITINGNCT05366881

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer...

Sponsor: Adela, IncEnrolling: 700017 locations
RECRUITINGPhase 1 / Phase 2NCT03190941

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of...

Background: A new cancer therapy involves taking white blood cells from a person, growing them in the lab, genetically modifying them, then giving them back to the person. This...

Sponsor: National Cancer Institute (NCI)Enrolling: 1101 location
RECRUITINGPhase 2NCT06436976

The Effect of Probiotics ATG-F4 in Cancer Patients

Patients with advanced colorectal cancer or pancreatic cancer who are receiving oxaliplatin-based chemotherapy will be included. The research participants in this study will...

Sponsor: Chungnam National University HospitalEnrolling: 301 location
RECRUITINGPhase 2NCT03935893

Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers

This is a Phase 2 study to evaluate the efficacy of a non-myeloablative lymphodepleting preparative regimen followed by infusion of autologous TIL and high-dose aldesleukin in...

Sponsor: Udai KammulaEnrolling: 2401 location
RECRUITINGPhase 1NCT06821048

Study of CEA Targeting CAR-T (PTC13) in the Treatment of CEA-Positive Advanced Malignant Solid Tumors

This is a phase I clinical study to evaluate the safety and tolerability of FAST targeted chimeric antigen receptor (CAR)-T cells (PTC13) in patients with carcinoembryonic antigen...

Sponsor: Weijia Fang, MDEnrolling: 181 location
RECRUITINGNCT06638866

AI-powered Early Detection for Pancreatic Cancer Via Non-contrast CT in Opportunistic Screening Cohort

Pancreatic ductal adenocarcinoma (PDAC) remains a therapeutic challenge with 5-year survival rates of 13%, primarily attributable to advanced-stage diagnosis (AJCC Stage III/IV in...

Sponsor: Changhai HospitalEnrolling: 50003 locations
RECRUITINGPhase 2NCT06491472

Ivonescimab(AK112/SMT112) in Combination With Stereotactic Body Radiation Therapy and Chemotherapy in Patients With...

This study is an open-label, single-arm Phase II clinical study to evaluate the efficacy and safety of ivonescimab(AK112/SMT112) in combination with stereotactic body radiation...

Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyEnrolling: 361 location
RECRUITINGPhase 1 / Phase 2NCT04195347

Study of CM4620 to Reduce the Severity of Pancreatitis Due to Asparaginase

This is a phase I/II clinical trial assessing the tolerability and efficacy of CM4620 in children and young adults with acute pancreatitis caused by asparaginase. The tolerability...

Sponsor: St. Jude Children's Research HospitalEnrolling: 422 locations
RECRUITINGPhase 4NCT05035147

Albumin-bound Paclitaxel Combined With Gemcitabine First-line Inoperable Pancreatic Cancer

This study aims to further observe and evaluate whether the three-week administration of albumin-bound paclitaxel combined with gemcitabine is equivalent to the four-week...

Sponsor: Tianjin Medical University Cancer Institute and HospitalEnrolling: 9341 location
RECRUITINGPhase 1 / Phase 2NCT06730009

Phase I/II Study: Allogeneic NK-cell Therapy With Chemotherapy for Post-Surgery PDA or Cholangiocarcinoma Patients

This is a phase I/II study which intends to characterize the safety, tolerability, and preliminary efficacy of Allogeneic Magicell-NK infusion in PDA or cholangiocarcinoma...

Sponsor: Medigen Biotechnology CorporationEnrolling: 421 location
RECRUITINGPhase 2NCT05088798

Utility of 18FDOPA PET/MRI for Focal Hyperinsulinism

The purpose of the study is to provide access to 18F-DOPA PET to patients at Washington University and assess the utility of 18F-DOPA PET/MRI as a preoperative tool to detect and...

Sponsor: Washington University School of MedicineEnrolling: 1001 location
RECRUITINGPhase 2NCT07114315

A Study of AK130 in Combination With AK112 for the Treatment of Advanced Pancreatic Cancer

This is an open-label, multi-center phase II clinical study consisting of two parts: Part I: To evaluate the safety and efficacy of AK130 combined with AK112 in advanced...

Sponsor: AkesoEnrolling: 1602 locations
RECRUITINGNCT06422455

Access to Genetic Testing in Underserved Patients With Cancer

This study compares the experiences of people who receive information about genetic testing from a computer-generated character to patients who receive information from a human...

Sponsor: University of Southern CaliforniaEnrolling: 8002 locations
RECRUITINGNCT06777030

Role of Exosomes in Pancreatic Cancer Progression

The present pilot study is set up with the objective of identifying circulating markers in the biological fluids (blood and urine) of subjects with pancreatic carcinoma and their...

Sponsor: IRCCS Azienda Ospedaliero-Universitaria di BolognaEnrolling: 601 location
RECRUITINGPhase 1 / Phase 2NCT05288205

Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation

This is a multicenter, open-label phase 1/2a study consisting of two parts: dose escalation phase and dose expansion phase. The objective of the dose escalation phase is to...

Sponsor: Allist Pharmaceuticals, Inc.Enrolling: 24020 locations
RECRUITINGNCT03637569

The Relationship Between Triceps Skinfold and Overall Survival of Pancreas, Bile Duct, Gallbladder Cancer

In this study, the investigators aim to demonstration of relationship between triceps skinfold thickness and overall survival of pancreatic cancer, cholangiocarcinoma and GB...

Sponsor: Samsung Medical CenterEnrolling: 10001 location
RECRUITINGNCT04291651

UCSF PANC Cyst Registry

Pancreatic cysts are found incidentally on 15-50% of CT and MRIs for all indications and their prevalence is increasing. Many of these cysts may be precursors to pancreatic...

Sponsor: University of California, San FranciscoEnrolling: 40001 location
RECRUITINGNCT06564571

Artificial Intelligence in Endoscopic Ultrasound

The objective of the study is to determine if this artificial intelligence system is capable of detecting abnormalities in the pancreas that are identified by an endoscopist at...

Sponsor: Orlando Health, Inc.Enrolling: 3101 location
RECRUITINGPhase 2NCT07110064

QL1706+Lenvatinib+AG Regimen as First-line Treatment for Advanced Metastatic Pancreatic Cancer

The investigators plan to initiate a prospective, multicenter, phase II study, recruiting 80 patients with advanced pancreatic cancer who have not received prior treatment. This...

Sponsor: Du JuanEnrolling: 801 location
RECRUITINGPhase 1 / Phase 2NCT06799637

Study of XNW28012 in Subjects with Advanced Solid Tumors Who Failed Standard Treatments

This is an open-label, dose escalation, multicenter, phase 1, first-in-human study of XNW28012 in subjects with advanced solid tumors who have failed current standard anti-tumor...

Sponsor: Evopoint Biosciences Inc.Enrolling: 20020 locations
RECRUITINGNCT07148830

Mesopancreatic Excision for Pancreatic Duct Adenocarcinoma.

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with high rates of local recurrence and distant metastasis. Recent evidence suggests that mesopancreatic excision...

Sponsor: Minia UniversityEnrolling: 1001 location
RECRUITINGNCT07007832

Bile Omics for Diagnosing Indeterminate Biliary Strictures

The diagnosis of malignant biliary strictures remains a challenging aspect of biliary endoscopy. Molecular biological testing techniques based on bile have been reported to...

Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineEnrolling: 2601 location
RECRUITINGNCT05275075

Identify microRNAs in Cachexia in Pancreatic Carcinoma

The purpose of this study is to determine the proportion of pancreatic patients who experience weight loss and cachexia, and to identify any differences in the genes between...

Sponsor: University of OklahomaEnrolling: 1001 location
RECRUITINGNCT03785743

Comparing Laparoscopic and Open Surgery for Pancreatic Carcinoma

Background: Pancreatic cancer (PC) is one of the most aggressive malignant neoplasms with poor outcomes. Pancreatoduodenectomy (PD) is the only curative treatment for PC....

Sponsor: Tongji HospitalEnrolling: 2001 location
RECRUITINGPhase 1NCT05969041

Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors

MYE Symphony is a multicenter, open-label, Phase 1 first-in-human study to assess the safety, tolerability, and define the RP2D of MT-302 in participants with advanced epithelial...

Sponsor: Myeloid TherapeuticsEnrolling: 486 locations
RECRUITINGPhase 1NCT06586515

MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

The main purpose of this study is to assess safety \& tolerability and antitumor activity of LY3962673 as monotherapy and in combination with other chemotherapy agents in...

Sponsor: Eli Lilly and CompanyEnrolling: 63020 locations
RECRUITINGNCT05117723

Intraductal Papillary Mucinous Neoplasm (IPMN) Database - A Tool to Predict Pancreatic Cancer

Pancreatic cancer is the 5th leading cause of cancer death in Australia. Surgery remains the most effective treatment for early pancreatic cancer and currently the only potential...

Sponsor: St Vincent's Hospital MelbourneEnrolling: 10001 location
RECRUITINGPhase 2NCT05518110

PaTcH Study: A Phase 2 Study of Trametinib and Hydroxychloroquine in Patients With Metastatic Refractory Pancreatic...

This study is designed to investigate the means by which cancer resists treatment can be overcome by a combination of an established anticancer drug, trametinib, with...

Sponsor: Cancer Trials IrelandEnrolling: 222 locations
RECRUITINGPhase 2NCT06345079

Cessation of Somatostatin Analogues After PRRT in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours

Neuroendocrine tumours (NETs) are slow growing cancers, which commonly present as metastatic incurable disease. Some neuroendocrine tumours, termed functional NETs, overproduce...

Sponsor: Australasian Gastro-Intestinal Trials GroupEnrolling: 7812 locations
RECRUITINGNCT04449406

Early Detection of Pancreatic Adenocarcinoma (PDAC) Using a Panel of Biomarkers

Urine and blood samples are being collected from patients with and without diseases of the pancreas. These samples will be tested with the aim of developing an accurate way of...

Sponsor: Queen Mary University of LondonEnrolling: 35004 locations
RECRUITINGNCT07463872

Management of Pancreatic Cystic Lesions Using Artificial Intelligence Based on EUS and Multimodal Data

The primary objective is to construct a multimodal AI model (Cyst-AI) based on EUS images and clinical data such as imaging features(CT or MRI) and laboratory tests to assist...

Sponsor: Huazhong University of Science and TechnologyEnrolling: 5002 locations
RECRUITINGPhase 1NCT06883539

A Phase I Study of LXP1788 Injection with Advanced Solid Tumors.

A Phase I, open-label, first-in-human study to determine the MTD, recommended phase 2 dose (RP2D), assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor...

Sponsor: LaunXP Biomedical Co., Ltd.Enrolling: 242 locations
RECRUITINGEarly Phase 1NCT07229768

Clinical Study of 177Lu-CTR-FAPI In the Treatment of Patients With Advanced, Metastatic Solid Tumors

This is a single-center, single-arm, open-label clinical study of 177Lu-CTR-FAPI injection in the treatment of patients with advanced, metastatic solid tumors i.e. pancreatic...

Sponsor: Yan XingEnrolling: 41 location
RECRUITINGNCT06151223

A Prospective Registry for Patients at High-Risk for Pancreatic Cancer

This study aims to facilitate discovery and validation of tests for early detection in subjects at high risk for pancreatic ductal adenocarcinoma (PDAC) and to facilitate the use...

Sponsor: Mayo ClinicEnrolling: 50001 location
RECRUITINGPhase 2NCT06850623

Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer

The purpose of the study is to assess the efficacy and safety of Acoustic Cluster Therapy (ACT) when given in addition to chemotherapy for treatment of Locally Advanced Pancreatic...

Sponsor: EXACT Therapeutics ASEnrolling: 2510 locations
RECRUITINGPhase 1NCT06344156

Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy as an Adjuvant Therapy for Pancreatic Cancer

The aim of this single center, single arm and prospective study is to explore the safety and efficacy of Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy in postoperative...

Sponsor: Sichuan UniversityEnrolling: 431 location
RECRUITINGNCT06842303

Contribution of New Pancreatic MRI Sequences for the Evaluation of Tumor Response in Pancreatic Adenocarcinomas

Pancreatic adenocarcinoma is the most pessimistic digestive cancer in terms of prognosis. Tumor response assessment is crucial, and the recent development of new magnetic...

Sponsor: Central Hospital, Nancy, FranceEnrolling: 1201 location
RECRUITINGPhase 1 / Phase 2NCT07148128

Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as...

This is a study designed to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of WEF-001 as monotherapy in patients with Advanced KRAS-mutant solid...

Sponsor: Auricula Biosciences Inc.Enrolling: 1104 locations
RECRUITINGPhase 2NCT06747845

Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not...

The main goal of this study is to look at the effectiveness and anti-tumor activity (preventing growth of the tumor) of the drugs niraparib and ipilimumab, on the patients and...

Sponsor: Abramson Cancer Center at Penn MedicineEnrolling: 682 locations
RECRUITINGNCT06388967

Pancreatic Cancer Detection Consortium

This study aims to prospective validate an exosome-based miRNA signature for noninvasive and early detection of pancreatic ductal adenocarcinoma.

Sponsor: City of Hope Medical CenterEnrolling: 200011 locations
RECRUITINGPhase 1 / Phase 2NCT03556228

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or...

Sponsor: VM Oncology, LLCEnrolling: 24215 locations
RECRUITINGNCT06717295

The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune...

The purpose of the CCANED-CIPHER study is to develop and validate an AI-based blood test for early cancer detection and to monitor treatment effectiveness in cancer patients. This...

Sponsor: Javier ToledoEnrolling: 60004 locations
RECRUITINGPhase 1 / Phase 2NCT06885034

A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With...

This study will check how well a new medicine, GSK5764227, works, how safe it is and how the body handles it in participants all around the world with advanced inoperable or...

Sponsor: GlaxoSmithKlineEnrolling: 32020 locations
RECRUITINGPhase 1NCT07114939

FTT PET/CT in Pancreatic Neuroendocrine Tumors

A pilot study to evaluate the expression of PARP-1 in patients with pancreatic neuroendocrine tumors will be conducted. This will be done via the use of a novel PET imaging agent,...

Sponsor: Abramson Cancer Center at Penn MedicineEnrolling: 121 location
RECRUITINGPhase 1 / Phase 2NCT05766748

Study of Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer

This is an open label study to determine the safety and preliminary evidence of a therapeutic effect of azeliragon in patients refractory to prior treatment of metastatic...

Sponsor: Cantex PharmaceuticalsEnrolling: 306 locations
RECRUITINGNCT04370574

Discovery of Soluble Biomarkers for Pancreatic Cancer Using Innovative All-Patient Inclusive Methodology

Pancreatic ductal adenocarcinoma (PDAC) remains among cancers with a very poor prognosis (1-year survival \<20%). Endoscopic ultrasound with fine needle aspiration (EUS/FNA) is...

Sponsor: University Hospital, MontpellierEnrolling: 2001 location
RECRUITINGPhase 1 / Phase 2NCT06385925

A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

The study is a first-in-human (FIH), open-label, multi-center phase 1/2 study of TSN1611 in subjects with KRAS G12D mutant advanced solid tumors. This study will consist of a...

Sponsor: Tyligand Pharmaceuticals (Suzhou) LimitedEnrolling: 44019 locations
RECRUITINGNCT06698458

Alpha Radiation Emitters Device (DaRT) With Chemotherapy for the Treatment of Locally Advanced and Metastatic...

This is a multi-center clinical study enrolling up to 30 participants (15 patients in each cohort). The primary objective of the study is to evaluate the safety of Alpha DaRT in...

Sponsor: Alpha Tau Medical LTD.Enrolling: 3015 locations
RECRUITINGNCT06855485

Efficacy and Safety of HANAROSTEN® HOT Plumber™ With Z-EUSIT™ for Pancreatic Pseudocyst Drainage

The goal of this prospective, single-center observational study is to evaluate the safety and effectiveness of the HANAROSTEN® HOT Plumber™ with Z-EUSIT™ for draining pancreatic...

Sponsor: Asan Medical CenterEnrolling: 201 location

Showing 50 of 113 trials.Search all Pancreatic Cancer trials

Frequently Asked Questions

There are currently 113 clinical trials for Pancreatic Cancer, with 113 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Pancreatic Cancer, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 3 Phase 3 trials for Pancreatic Cancer, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice — always talk to your doctor about clinical trial participation.